CXCL8 and hepatocellular carcinoma: In the presented exploratory study, we define baseline levels of IL-6 and IL-8 as prognostic biomarkers of overall survival in patients with advanced HCC undergoing sorafenib treatment by identifying cut-off values of 8.58 pg/mL and 57.9 pg/mL for IL-6 and IL-8, respectively.